No Data
Cantor Fitzgerald Reiterates Overweight on Pfizer, Maintains $45 Price Target
Cantor Fitzgerald analyst Louise Chen reiterates Pfizer (NYSE:PFE) with a Overweight and maintains $45 price target.
Pfizer Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/01/2024 58.81% Cantor Fitzgerald $45 → $45 Reiterates Overweight → Overweight 06/26/2024 58.81% Cantor
Bridgepoint Announces Director's New Pfizer Role
Vera Therapeutics Appoints David Johnson as Chief Operating Officer
Vera Therapeutics (VERA) said Monday it appointed David Johnson as Chief Operating Officer, effective immediately. Before joining Vera, Johnson served as the Chief Commercial Officer at Global Blood T
Should You Expect Upside Potential For Pfizer (PFE)?
Express News | Cyrus Taraporevala Elected to Pfizer’s Board of Directors